Serum Leptin and Triglyceride Levels in Patients on Treatment With Atypical Antipsychotics
J Clin Psychiatry 2003;64:598-604
© Copyright 2014 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Background: Weight gain is a common adverse
effect associated with the use of most antipsychotic drugs.
Leptin has been reported to be associated with
antipsychotic-induced weight gain. Previous studies have
demonstrated a relationship between the atypical antipsychotics
clozapine and olanzapine and serum leptin levels. We planned to
comparatively investigate the effects of the atypical
antipsychotics quetiapine, olanzapine, risperidone, and clozapine
on leptin and triglyceride levels and weight gain.
Method: The study population comprised 56
patients with DSM-IV schizophrenia, who were divided into 4
treatment groups: quetiapine (N = 14), olanzapine (N = 14),
risperidone (N = 14), or clozapine (N = 14) monotherapy, and a
control group of 11 patients receiving no psychopharmacologic
treatment. The patients were evaluated at baseline and at the
sixth week according to the Positive and Negative Syndrome Scale
(PANSS), body mass index (BMI), weight, and fasting serum leptin
and triglyceride levels. Data were gathered in 2001 and 2002.
Results: Olanzapine and clozapine caused a
marked increase in weight and serum triglyceride and leptin
levels, though increases in these variables were modest in the
patients receiving quetiapine and minimal in those receiving
risperidone. There were positive correlations between serum
leptin levels and BMI and triglyceride levels. Clinical efficacy,
as indicated by decrease in total PANSS scores, was associated
with leptin levels in all atypical antipsychotic groups.
Conclusion: Our results suggest that leptin may
be associated with olanzapine- and clozapine-induced weight gain
and that quetiapine appears to have modest influence and
risperidone appears to have minimal influence on leptin and
triglyceride levels and weight gain compared with olanzapine and